Loading...
Loading...
In a report published Tuesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Gilead Sciences
GILD, and raised the price target from $48.00 to $69.00.
In the report, Karnauskas noted, “We built a monthly HCV market model and analyzed prior treatment trends to derive our estimates for 14,15-16, and 17+ as GILD plans to provide some color YE on these markets. Our conclusion is that SOF can sell WW $3.7B, $8.4B, $12.4B in 14, 15, and peak respectively. We analyzed the co's new HIV drug TAF and now include its impact in our model. Maintain Buy.”
Gilead Sciences closed on Monday at $50.67.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in